The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
And the move will shake up the orthopaedic robotics scene.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.